Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Acquired by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. lifted its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 109.0% during the second quarter, Holdings Channel reports. The firm owned 14,696 shares of the company’s stock after buying an additional 7,664 shares during the period. E Fund Management Co. Ltd.’s holdings in Apellis Pharmaceuticals were worth $564,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Norges Bank acquired a new stake in shares of Apellis Pharmaceuticals during the 4th quarter worth approximately $56,640,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Apellis Pharmaceuticals during the first quarter valued at $3,218,000. Bellevue Group AG raised its stake in shares of Apellis Pharmaceuticals by 3.5% during the fourth quarter. Bellevue Group AG now owns 821,800 shares of the company’s stock valued at $49,193,000 after purchasing an additional 27,959 shares in the last quarter. Edgestream Partners L.P. acquired a new stake in Apellis Pharmaceuticals in the first quarter worth about $942,000. Finally, Altitude Crest Partners Inc. bought a new position in Apellis Pharmaceuticals in the 4th quarter valued at about $9,111,000. 96.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 37,000 shares of the stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $36.23, for a total value of $1,340,510.00. Following the completion of the sale, the director now owns 100,000 shares in the company, valued at approximately $3,623,000. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 6.80% of the stock is currently owned by insiders.

Apellis Pharmaceuticals Stock Performance

Shares of Apellis Pharmaceuticals stock opened at $35.63 on Thursday. Apellis Pharmaceuticals, Inc. has a 12 month low of $33.49 and a 12 month high of $73.80. The company has a quick ratio of 4.18, a current ratio of 5.08 and a debt-to-equity ratio of 1.73. The stock has a market cap of $4.32 billion, a PE ratio of -10.30 and a beta of 0.88. The business has a fifty day simple moving average of $38.05 and a 200-day simple moving average of $44.06.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.03. The firm had revenue of $199.70 million during the quarter, compared to analyst estimates of $190.89 million. Apellis Pharmaceuticals had a negative return on equity of 138.32% and a negative net margin of 52.99%. The business’s quarterly revenue was up 110.2% compared to the same quarter last year. During the same period last year, the company posted ($1.02) EPS. On average, sell-side analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.29 EPS for the current fiscal year.

Wall Street Analyst Weigh In

APLS has been the subject of a number of research analyst reports. The Goldman Sachs Group upped their price target on shares of Apellis Pharmaceuticals from $66.00 to $74.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Piper Sandler initiated coverage on Apellis Pharmaceuticals in a research report on Friday, May 31st. They issued a “neutral” rating and a $46.00 target price for the company. HC Wainwright lowered their price target on Apellis Pharmaceuticals from $92.00 to $83.00 and set a “buy” rating on the stock in a research report on Friday, August 2nd. Robert W. Baird upped their price objective on Apellis Pharmaceuticals from $86.00 to $96.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Finally, Wells Fargo & Company lowered their target price on Apellis Pharmaceuticals from $57.00 to $48.00 and set an “equal weight” rating on the stock in a report on Thursday, May 23rd. Four research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $71.67.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).